Supporting Information

Maximiscin induces DNA damage, activates DNA damage response pathways and has selective cytotoxic activity against a subtype of triple negative breast cancer

Andrew J. Robles,[†] Lin Du,[§,⊥] Robert H. Cichewicz,[*,§,⊥] and Susan L. Mooberry[*,†,‡]

[†]Department of Pharmacology, and [‡]Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900, United States. [§]Natural Product Discovery Group, Institute for Natural Products Applications and Research Technologies and [⊥]Department of Chemistry & Biochemistry, Stephenson Life Science Research Center, University of Oklahoma, 101 Stephenson Parkway, Norman, Oklahoma 73019-0390, United States.

TABLE OF CONTENTS



Figure S1. Compound **1** (maximiscin) and pyridoxatin have nearly identical potency and efficacy in MDA-MB-468 cells. SRB assay concentration-response curves for maxmiscin and pyridoxatin in MDA-MB-468 cells after 48 h of treatment.



Figure S2. Compound **1** (maximiscin) induces p53 phosphorylation in MDA-MB-468 cells. Intracellular signaling antibody array data for P-S15-p53. MDA-MB-468 cells were treated with 1 μM maximiscin for various time points prior to lysis and analysis of the extract on the antibody array.